Screener
Dyne Therapeutics, Inc. DYN Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Vendor financing arrangement | 6,224 | — |
| Lease liabilities | 5,033 | 4,995 |
| Total current liabilities | 51,249 | 50,625 |
| Long-term debt, net | 149,375 | 148,921 |
| Lease liabilities, net of current portion | 14,271 | 15,283 |
| Total liabilities | 214,895 | 214,829 |
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025 | — | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s long-term debt?
- Dyne Therapeutics, Inc. (DYN) reported long-term debt of $149.38M in Q1 2026.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Dyne Therapeutics, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude